Objective:This study aimed to explore the efficacy and safety of Qingxin Fupi Jieyu formula(the herbal formula has the function of clear away the heart fire,tonify spleen,and relieve depression,QXFPJYF)in treating dig...Objective:This study aimed to explore the efficacy and safety of Qingxin Fupi Jieyu formula(the herbal formula has the function of clear away the heart fire,tonify spleen,and relieve depression,QXFPJYF)in treating digestive tract cancer-related cognitive impairment(CRCI).Methods:28 subjects with digestive tract CRCI were treated with QXFPJYF for 6 weeks.The scores of Montreal Cognitive Assessment and Mini-Mental State Examination were observed at four-time points(baseline,week 2,week 4,week 6).Besides,anxiety and depression scores and tumor markers were measured.Results:The scores of Montreal Cognitive Assessment and various fields were elevated steadily after treatment,such as visuospatial/executive,attention,language,delayed recall,and orientation.The differences were statistically significant(P<0.05)besides language score.The scores of Mini-Mental State Examination and various factors were elevated gradually at week 2,week 4 and week 6,including language and praxis,attention and calculation,recall and orientation,and the differences were statistically significant(P<0.05)except for recall score.The results also showed the change of tumor markers were not obvious,but anxious and depressed emotions were improved.More importantly,no subjects developed with obvious adverse reactions during the study.Conclusion:The finding indicated that QXFPJYF treated digestive tract CRCI with great efficacy and safety,which improved cognitive function from several fields.Nevertheless,the current study was limited by sample and medical ethics,and which was a self-control trial,some limitations needed to be acknowledged,further high-quality research is required to explore and verify it.展开更多
目的评价抑肝扶脾汤治疗腹泻型肠易激综合征(irritable bowel syndrome with diarrhea,IBS-D)的有效性和安全性。方法将患者按随机数字表法分为治疗组和对照组,每组58例。治疗组给予抑肝扶脾汤治疗,对照组给予口服匹维溴铵片,2组疗程均...目的评价抑肝扶脾汤治疗腹泻型肠易激综合征(irritable bowel syndrome with diarrhea,IBS-D)的有效性和安全性。方法将患者按随机数字表法分为治疗组和对照组,每组58例。治疗组给予抑肝扶脾汤治疗,对照组给予口服匹维溴铵片,2组疗程均为4周。分别采用IBS症状尺度表(IBS bowel symptom severity scale,IBS-BSS)、IBS大便性状问卷(IBS defecation state questionnaire,IBS-DSQ)、IBS生活质量问卷(IBS quality of life questionnaire,IBS-QOL)和中医证候疗效评分表(traditional Chinese medicine pattern curative effect scoring system,TCM-PES)评估两组患者治疗后总体临床疗效、大便性状情况、生活质量及中医证候疗效。结果治疗组与对照组IBS-BSS总有效率(分别为82.76%、77.59%)比较,差异无统计学意义(P>0.05),IBS-BSS总积分比较,治疗组低于对照组(P<0.05);两组大便性状总有效率(分别为81.03%、72.41%)比较,差异有统计学意义(P<0.05),且治疗组在10天中排便的急迫天数短于对照组(P<0.05);两组IBS-QOL总积分、中医证候总有效率(分别为84.48%、70.69%)及中医证侯总积分方面均有改善,且治疗组优于对照组(P<0.05)。结论抑肝扶脾汤能有效缓解IBS-D肝气乘脾证患者肠道症状,改善大便性状及频率,提高患者生活质量,改善肝气乘脾证候,且有良好的安全性和依从性。展开更多
目的:观察扶脾柔肝方配方颗粒对肝纤维化大鼠肝组织诱导型一氧化氮合酶(i NOS)表达的影响,并探讨其作用机制。方法:SD大鼠按随机数字表法分为正常组、模型组、秋水仙碱(0.2 mg·kg-1)组、扶正化瘀(0.415 g·kg-1)组、扶脾柔肝...目的:观察扶脾柔肝方配方颗粒对肝纤维化大鼠肝组织诱导型一氧化氮合酶(i NOS)表达的影响,并探讨其作用机制。方法:SD大鼠按随机数字表法分为正常组、模型组、秋水仙碱(0.2 mg·kg-1)组、扶正化瘀(0.415 g·kg-1)组、扶脾柔肝方配方颗粒高、中、低剂量(80,40,20 g·kg-1)组,采用四氯化碳复合乙醇诱导大鼠肝纤维化模型,造模8周成功后,分别给予相应药物ig,每日1次,连续4周,正常组、模型组ig等体积生理盐水。第12周末,检测大鼠血清丙氨酸氨基转移酶(ALT),天门冬氨酸氨基酸转移酶(AST),透明质酸(HA);苏木素伊红(HE)染色观察肝组织病理情况;采用实时荧光定量PCR(Realtime PCR)及免疫印迹法(Western blot)检测大鼠肝组织i NOS mRNA和蛋白表达水平。结果:与正常组比较,模型组大鼠血清中ALT,AST,HA含量显著升高(P<0.01);与模型组比较,秋水仙碱组、扶正化瘀组、扶脾柔肝方低、中剂量组血清中的ALT,AST含量均明显降低(P<0.05),高剂量组ALT,AST含量显著降低(P<0.01),秋水仙碱组、扶正化瘀组、扶脾柔肝方中剂量组血清中的HA含量明显降低(P<0.05),扶脾柔肝方高剂量组HA含量显著降低(P<0.01)。与模型组比较,各药物干预组肝组织内纤维化程度均有不同程度减轻(P<0.05)。与正常组比较,模型组大鼠肝组织i NOS mRNA和蛋白表达显著升高(P<0.01);与模型组比较,各药物干预组大鼠肝组织i NOS mRNA和蛋白表达显著降低(P<0.01),其中以扶脾柔肝方高剂量组最明显。结论:扶脾柔肝方配方颗粒下调纤维化肝组织i NOS mRNA和蛋白表达水平,可能是其抗肝纤维化作用机制之一。展开更多
文摘Objective:This study aimed to explore the efficacy and safety of Qingxin Fupi Jieyu formula(the herbal formula has the function of clear away the heart fire,tonify spleen,and relieve depression,QXFPJYF)in treating digestive tract cancer-related cognitive impairment(CRCI).Methods:28 subjects with digestive tract CRCI were treated with QXFPJYF for 6 weeks.The scores of Montreal Cognitive Assessment and Mini-Mental State Examination were observed at four-time points(baseline,week 2,week 4,week 6).Besides,anxiety and depression scores and tumor markers were measured.Results:The scores of Montreal Cognitive Assessment and various fields were elevated steadily after treatment,such as visuospatial/executive,attention,language,delayed recall,and orientation.The differences were statistically significant(P<0.05)besides language score.The scores of Mini-Mental State Examination and various factors were elevated gradually at week 2,week 4 and week 6,including language and praxis,attention and calculation,recall and orientation,and the differences were statistically significant(P<0.05)except for recall score.The results also showed the change of tumor markers were not obvious,but anxious and depressed emotions were improved.More importantly,no subjects developed with obvious adverse reactions during the study.Conclusion:The finding indicated that QXFPJYF treated digestive tract CRCI with great efficacy and safety,which improved cognitive function from several fields.Nevertheless,the current study was limited by sample and medical ethics,and which was a self-control trial,some limitations needed to be acknowledged,further high-quality research is required to explore and verify it.
文摘目的评价抑肝扶脾汤治疗腹泻型肠易激综合征(irritable bowel syndrome with diarrhea,IBS-D)的有效性和安全性。方法将患者按随机数字表法分为治疗组和对照组,每组58例。治疗组给予抑肝扶脾汤治疗,对照组给予口服匹维溴铵片,2组疗程均为4周。分别采用IBS症状尺度表(IBS bowel symptom severity scale,IBS-BSS)、IBS大便性状问卷(IBS defecation state questionnaire,IBS-DSQ)、IBS生活质量问卷(IBS quality of life questionnaire,IBS-QOL)和中医证候疗效评分表(traditional Chinese medicine pattern curative effect scoring system,TCM-PES)评估两组患者治疗后总体临床疗效、大便性状情况、生活质量及中医证候疗效。结果治疗组与对照组IBS-BSS总有效率(分别为82.76%、77.59%)比较,差异无统计学意义(P>0.05),IBS-BSS总积分比较,治疗组低于对照组(P<0.05);两组大便性状总有效率(分别为81.03%、72.41%)比较,差异有统计学意义(P<0.05),且治疗组在10天中排便的急迫天数短于对照组(P<0.05);两组IBS-QOL总积分、中医证候总有效率(分别为84.48%、70.69%)及中医证侯总积分方面均有改善,且治疗组优于对照组(P<0.05)。结论抑肝扶脾汤能有效缓解IBS-D肝气乘脾证患者肠道症状,改善大便性状及频率,提高患者生活质量,改善肝气乘脾证候,且有良好的安全性和依从性。
文摘目的:观察扶脾柔肝方配方颗粒对肝纤维化大鼠肝组织诱导型一氧化氮合酶(i NOS)表达的影响,并探讨其作用机制。方法:SD大鼠按随机数字表法分为正常组、模型组、秋水仙碱(0.2 mg·kg-1)组、扶正化瘀(0.415 g·kg-1)组、扶脾柔肝方配方颗粒高、中、低剂量(80,40,20 g·kg-1)组,采用四氯化碳复合乙醇诱导大鼠肝纤维化模型,造模8周成功后,分别给予相应药物ig,每日1次,连续4周,正常组、模型组ig等体积生理盐水。第12周末,检测大鼠血清丙氨酸氨基转移酶(ALT),天门冬氨酸氨基酸转移酶(AST),透明质酸(HA);苏木素伊红(HE)染色观察肝组织病理情况;采用实时荧光定量PCR(Realtime PCR)及免疫印迹法(Western blot)检测大鼠肝组织i NOS mRNA和蛋白表达水平。结果:与正常组比较,模型组大鼠血清中ALT,AST,HA含量显著升高(P<0.01);与模型组比较,秋水仙碱组、扶正化瘀组、扶脾柔肝方低、中剂量组血清中的ALT,AST含量均明显降低(P<0.05),高剂量组ALT,AST含量显著降低(P<0.01),秋水仙碱组、扶正化瘀组、扶脾柔肝方中剂量组血清中的HA含量明显降低(P<0.05),扶脾柔肝方高剂量组HA含量显著降低(P<0.01)。与模型组比较,各药物干预组肝组织内纤维化程度均有不同程度减轻(P<0.05)。与正常组比较,模型组大鼠肝组织i NOS mRNA和蛋白表达显著升高(P<0.01);与模型组比较,各药物干预组大鼠肝组织i NOS mRNA和蛋白表达显著降低(P<0.01),其中以扶脾柔肝方高剂量组最明显。结论:扶脾柔肝方配方颗粒下调纤维化肝组织i NOS mRNA和蛋白表达水平,可能是其抗肝纤维化作用机制之一。
